KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
Europe - FRA:PHI1 - NL0000009538 - Common Stock
24.57 EUR
+0.12 (+0.49%)
PHI1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
PHI1 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
Of the past 5 years PHI1 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PHI1 (0.61%) is worse than 62.71% of its industry peers.
The Return On Equity of PHI1 (1.56%) is worse than 62.71% of its industry peers.
With a Return On Invested Capital value of 4.00%, PHI1 perfoms like the industry average, outperforming 40.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROIC | 4% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHI1's Profit Margin of 0.91% is on the low side compared to the rest of the industry. PHI1 is outperformed by 62.71% of its industry peers.
PHI1 has a Operating Margin of 6.11%. This is comparable to the rest of the industry: PHI1 outperforms 44.07% of its industry peers.
PHI1's Operating Margin has declined in the last couple of years.
PHI1 has a Gross Margin of 43.85%. This is in the lower half of the industry: PHI1 underperforms 71.19% of its industry peers.
In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
The number of shares outstanding for PHI1 has been increased compared to 5 years ago.
Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
2.2 Solvency
PHI1 has an Altman-Z score of 1.95. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.95, PHI1 is in line with its industry, outperforming 40.68% of the companies in the same industry.
The Debt to FCF ratio of PHI1 is 19.41, which is on the high side as it means it would take PHI1, 19.41 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PHI1 (19.41) is worse than 61.02% of its industry peers.
A Debt/Equity ratio of 0.69 indicates that PHI1 is somewhat dependend on debt financing.
PHI1's Debt to Equity ratio of 0.69 is on the low side compared to the rest of the industry. PHI1 is outperformed by 76.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 1.95 |
ROIC/WACC0.62
WACC6.46%
2.3 Liquidity
A Current Ratio of 1.26 indicates that PHI1 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.26, PHI1 is doing worse than 62.71% of the companies in the same industry.
A Quick Ratio of 0.81 indicates that PHI1 may have some problems paying its short term obligations.
PHI1 has a Quick ratio of 0.81. This is in the lower half of the industry: PHI1 underperforms 67.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 |
3. Growth
3.1 Past
PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.17%, which is quite good.
PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.53% in the last year.
The Revenue has been growing slightly by 1.00% on average over the past years.
EPS 1Y (TTM)11.17%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%21.91%
Revenue 1Y (TTM)-1.53%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-2.12%
3.2 Future
PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.26% yearly.
The Revenue is expected to grow by 3.26% on average over the next years.
EPS Next Y0.42%
EPS Next 2Y5.48%
EPS Next 3Y7.81%
EPS Next 5Y12.26%
Revenue Next Year-1.83%
Revenue Next 2Y0.64%
Revenue Next 3Y1.91%
Revenue Next 5Y3.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.06, which indicates a rather expensive current valuation of PHI1.
Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 88.14% of the companies listed in the same industry.
PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.77.
The Price/Forward Earnings ratio is 15.94, which indicates a correct valuation of PHI1.
71.19% of the companies in the same industry are more expensive than PHI1, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.23. PHI1 is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 15.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 71.19% of the companies are valued more expensively.
PHI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.51 | ||
| EV/EBITDA | 12.68 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)41.11
PEG (5Y)N/A
EPS Next 2Y5.48%
EPS Next 3Y7.81%
5. Dividend
5.1 Amount
PHI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHI1 (10/21/2025, 7:00:00 PM)
24.57
+0.12 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners47.54%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.66B
Revenue(TTM)17.86B
Net Income(TTM)162.00M
Analysts74.81
Price Target27.28 (11.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.64%
Min EPS beat(2)22.24%
Max EPS beat(2)31.04%
EPS beat(4)2
Avg EPS beat(4)6.19%
Min EPS beat(4)-16.56%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-1.09%
EPS beat(12)5
Avg EPS beat(12)15.29%
EPS beat(16)5
Avg EPS beat(16)3.51%
Revenue beat(2)0
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-1.61%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-0.47%
PT rev (3m)5.73%
EPS NQ rev (1m)-0.38%
EPS NQ rev (3m)-3.82%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-8.66%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-3.44%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-2.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 15.94 | ||
| P/S | 1.32 | ||
| P/FCF | 54.51 | ||
| P/OCF | 21.53 | ||
| P/B | 2.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.68 |
EPS(TTM)1.44
EY5.86%
EPS(NY)1.54
Fwd EY6.27%
FCF(TTM)0.45
FCFY1.83%
OCF(TTM)1.14
OCFY4.65%
SpS18.54
BVpS10.78
TBVpS-1.76
PEG (NY)41.11
PEG (5Y)N/A
Graham Number18.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROCE | 5.69% | ||
| ROIC | 4% | ||
| ROICexc | 4.43% | ||
| ROICexgc | 14.55% | ||
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% | ||
| FCFM | 2.43% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-Score8
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 3.01 | ||
| Cap/Depr | 51.35% | ||
| Cap/Sales | 3.72% | ||
| Interest Coverage | 4 | ||
| Cash Conversion | 46.06% | ||
| Profit Quality | 267.9% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 | ||
| Altman-Z | 1.95 |
F-Score8
WACC6.46%
ROIC/WACC0.62
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.17%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%21.91%
EPS Next Y0.42%
EPS Next 2Y5.48%
EPS Next 3Y7.81%
EPS Next 5Y12.26%
Revenue 1Y (TTM)-1.53%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-2.12%
Revenue Next Year-1.83%
Revenue Next 2Y0.64%
Revenue Next 3Y1.91%
Revenue Next 5Y3.26%
EBIT growth 1Y476.21%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.14%
EBIT Next 3Y21.01%
EBIT Next 5YN/A
FCF growth 1Y3516.67%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y43.47%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%